Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00814086
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:47.005971+00:00
Published At
2014-12-31T00:00:00+00:00
Record Updated At
2014-12-31
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Chemotherapeutic Agent Toxicity", "Endometrial Adenocarcinoma", "Fallopian Tube Carcinoma", "Gastrointestinal Complication", "Malignant Ovarian Mixed Epithelial Tumor", "Neurotoxicity Syndrome", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Primary Peritoneal Carcinoma", "Stage II Ovarian Cancer", "Stage III Ovarian Cancer", "Stage IV Ovarian Cancer", "Undifferentiated Ovarian Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2014-12-31"
protocolSection.identificationModule.nctId
"NCT00814086"
protocolSection.identificationModule.officialTitle
"A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Chemotherapeutic Agent Toxicity (protocolSection.conditionsModule.conditions)
  • Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Gastrointestinal Complication (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Mixed Epithelial Tumor (protocolSection.conditionsModule.conditions)
  • Neurotoxicity Syndrome (protocolSection.conditionsModule.conditions)
  • Ovarian Brenner Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage II Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage III Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Undifferentiated Ovarian Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.